After adjusting for stage of breast cancer, the result showed that female patients with breast cancer undergoing GnRH agonist therapy had a significantly decreased risk of incident IHD (HR: 0.57, 95% CI: 0.38–0.84, p = 0.004) (Table S1). Here, GNRH1 is linked to breast cancer.